Streetbeat News

Products Services

OPTN

Optinose announced a corporate update, expecting to achieve positive income from operations by 2025. Preliminary Q1 2024 XHANCE net product revenue is $14.9 million, a 26% increase from Q1 2023. Peak XHANCE revenues are anticipated to exceed $300 million, targeting ENT and Allergy specialists.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:29 am

REGN

Regeneron Pharmaceuticals and Mammoth Biosciences have entered into a partnership to develop next-generation CRISPR-based gene editing therapies for multiple diseases. Mammoth will receive a total of $100 million upfront, including a $95 million equity investment from Regeneron, with potential future payments up to $370 million per target, plus royalties on sales.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:28 am

PPBT

Purple Biotech announced that its Phase 2 study of CM24 for pancreatic cancer has been selected for a late-breaking abstract poster presentation at the ASCO 2024 Annual Meeting. This recognition could indicate significant progress in the company's cancer treatment research.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:25 am

HOOK

HOOKIPA Pharma has announced the final pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab, following alignment with the FDA. This marks a significant step forward in the development of HB-200 for treating patients, potentially impacting HOOK's stock in the short term.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:24 am

ONCY

Oncolytics Biotech announced the acceptance of two abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This development could signal positive progress in their research and potential for future growth.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:24 am

PLTR

Parexel and Palantir Technologies have announced a multi-year strategic partnership to enhance and accelerate clinical trials using AI. Parexel will use Palantir's Foundry and AIP to improve its clinical data platform, aiming to boost trial efficiency and safety. This marks the first time a CRO collaborates with Palantir in such a capacity, expanding on their year-long cooperation.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:23 am

GM

General Motors (NYSE:GM) announced plans to relaunch its autonomous driving unit, Cruise, after a temporary halt due to a robotaxi accident. The company is focusing on building regulator and customer trust, enhancing safety, and expects $1.7 billion in expenses for Cruise this year. Operations have resumed in Phoenix with manual driving to collect road data, aiming for a gradual return to driverless operations. GM is exploring funding options for Cruise, including external investments.

Portfolio Pulse from Anan Ashraf

April 25, 2024 | 11:17 am

NEM

Newmont Corporation projects its FY24 attributable gold production to reach 6,930K ounces, indicating a significant production outlook.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:10 am

META

Meta Platforms Inc. (NASDAQ:META) CEO Mark Zuckerberg announced that the new version of Meta AI, powered by the Llama 3 model, has been positively received, with tens of millions of users trying it out. The initial rollout in English-speaking countries is going well, with plans to expand to more languages and countries. Zuckerberg highlighted Meta's product development strategy of releasing early versions to a limited audience, gathering feedback, and then improving the product. The Llama 3 AI model competes with Google Gemini and Anthropic's Claude 3, offering unique features like creating animations from still images.

Portfolio Pulse from Rounak Jain

April 25, 2024 | 11:05 am

KO

MSFT

PEP

PepsiCo Inc (NASDAQ:PEP) exceeded Q1 earnings and revenue expectations despite weaker U.S. demand and Quaker Oats recalls. Revenue grew 2.3% to $18.25 billion, and net income reached $2.04 billion. However, Pepsi shares fell 2% due to concerns over the struggling domestic market. Volume was pressured, with the beverage segment flat and food division volume down 0.5%. The North American Quaker Food division saw a 22% volume drop due to recalls. Despite domestic challenges, international segments showed growth. Pepsi reaffirmed its full-year outlook for organic revenue growth and core constant currency earnings per share increase. Meanwhile, The Coca Cola Company (NYSE:KO) announced a strategic partnership with Microsoft Corporation (NASDAQ:MSFT) to accelerate cloud and AI development, posing potential competition for Pepsi.

Portfolio Pulse from Upwallstreet

April 25, 2024 | 10:49 am